Paxlovid May Not Be Associated With Lower Long COVID Risk, Survey Suggests

(MedPage Today) -- Nirmatrelvir-ritonavir (Paxlovid) did not reduce the odds of developing long COVID in vaccinated, non-hospitalized adults, survey data showed. About 16% of those treated with nirmatrelvir-ritonavir during acute infection with...
Source: MedPage Today Infectious Disease - Category: Infectious Diseases Source Type: news